New Therapeutic Developments for Relapsed/Refractory Multiple Myeloma

Download All

In this online program, experts discuss how to best use new therapeutic agents for patients with relapsed/refractory multiple myeloma. Watch the on-demand Webcast and download the slides from a dynamic online live CCO symposium, plus access expert commentaries and a podcast on the new data to learn more about how to select optimal regimens for your patients with advanced myeloma.

This educational program is intended for clinicians practicing medicine outside of the United States.

person default
Paula Rodriguez-Otero, MD, PhD
Jesús F. San-Miguel, MD, PhD

ClinicalThought

How will you incorporate belantamab mafodotin into your clinical practice for patients with relapsed/refractory multiple myeloma? Here are my thoughts.

This educational activity is intended for clinicians practicing medicine outside of the United States.

person default Paula Rodriguez-Otero, MD, PhD Released: August 25, 2020

Read my thoughts on treating patients with multiple myeloma who experience biochemical relapse.

This educational activity is intended for clinicians practicing medicine outside of the United States.

Jesús F. San-Miguel, MD, PhD Released: September 22, 2020
Provided by Clinical Care Options, LLC, in partnership with Clinical Care Options Global B.V.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
GlaxoSmithKline

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings